IP Library Granted Patent US 10,316,301
Granted Patent B2
US 10,316,301 · App. 15/348,077 · Granted Jun 11, 2019

Tailored recombinase for recombining asymmetric target sites in a plurality of retrovirus strains

Inventors: Joachim Hauber (Hamburg, DE); Jan Chemnitz (Oederquart, DE); Frank Buchholz (Dresden, DE); Janet Chusainow (Dresden, DE)
Assignees: Heinrich-Pette-Institut, Leibniz-Institut für Experimentelle Virologie; Max-Planck-Gesellschaft Zur Förderung der Wissenschaften E.V.
C12N9/1241C12N9/22C12N15/1058C12N2740/16022
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,316,301
App. No.
15/348,077
Granted
Jun 11, 2019
Kind
B2
Abstract

The present invention relates to a method for preparing an expression vector encoding a tailored recombinase, which tailored recombinase is capable of recombining asymmetric target sequences within the long terminal repeat (LTR) of proviral DNA of a plurality of retrovirus strains inserted into the genome of a host cell, as well as to the obtained expression vector, cells transfected with this, expressed recombinase and pharmaceutical compositions comprising the expression vector, cells and/or recombinase. Pharmaceutical compositions are useful, e.g., in treatment and/or prevention of retrovirus infection. In particular, asymmetric target sequences present in a plurality of HIV strains are disclosed, as well as tailored recombinases capable of combining these sequences (Tre 3.0 and 4.0) and expression vectors encoding them.

Claims (7)

1. An evolution vector comprising a nucleic acid selected from the group consisting of SEQ ID NOS: 1, 2, and 8-15, wherein the evolution vector further encodes a recombinase, and wherein expression of the recombinase is controlled by an inducible promoter.

2. The evolution vector of claim 1 , comprising the nucleic acid of SEQ ID NO: 1.

3. The evolution vector of claim 1 , comprising the nucleic acid of SEQ ID NO: 2.

4. The evolution vector of claim 1 , wherein the evolution vector is a plasmid.

5. The evolution vector of claim 1 , wherein the vector is capable of being recombined by a tailored recombinase comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 40-64.

6. The evolution vector of claim 1 , wherein the recombinase is selected from the group comprising Cre, Tre, Dre, Zre and Shew.

7. The evolution vector of claim 1 , wherein the recombinase is a randomly mutated recombinase.

Assignments (1)
CHANGE OF NAME Recorded Jun 7, 2022
From: HEINRICH-PETTE-INSTITUT, LEIBNIZ-INSTITUT FÜR EXPERIMENTELLE VIROLOGIE
To: LEIBNIZ-INSTITUT FÜR VIROLOGIE
Reel/Frame 060305/0386 →
Priority Claims (1)
EP 10005499 · May 27, 2010 · regional
Continuity (3)
Continuation 14560795 · Dec 4, 2014
Continuation 13698410
Related Publication 20170130212A1 · May 11, 2017